The natural substance thus underlines a multi-targeting potential recommending it as a co-therapeutic for CRC, especially as it modulates the carcinogenesis in all stages (initiation, promotion, progression) and even enhances the effect of classic chemotherapeutic agents through this synergistic interaction with p53. The gene discussed is TP53; the disease is colorectal carcinoma.